Ayu Mayangsari
Department of Medicine, Faculty of Medicine, University of Muhammadiyah Surakarta, Indonesia

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

The Effect of Vitamin D Supplementation in Pregnant Woman for Pre-eclampsia Incidency : A Literature Review Tia Mella Citra; Ratih Pramuningtyas; Tri Agustina; Erna Herawati; Ayu Mayangsari; Zhela Fatin Fatiha; Aulia Nissa Rizky Hariyono
Journal Research of Social Science, Economics, and Management Vol. 2 No. 3 (2022): Journal Research of Social Science, Economics, and Management
Publisher : Publikasi Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1811.023 KB) | DOI: 10.59141/jrssem.v2i03.252

Abstract

Pre-eclampsia was defined as hypertension after 20 weeks of gestation with evidence of maternal organ dysfunction,uteroplacental, or proteinuria. Maternal vitamin D deficiency may be with an increased risk of pre-eclampsia. Nonetheless, To assess the impact of vitamin D supplementation on the risk of pre-eclampsia, we performed a literature review. We researched Google Scholar; PubMed; Research Gate; and Science Directs using keyword (“Vitamin D” OR “Hydroxyvitamin D (25(OH)D)”OR “25(OH)D” OR “25hydroxycholecalciferol”) AND (“Pregnancy” OR “Pregnant women” OR “Gestation”) AND (“Clinical trial” OR “Clinical study” OR “study” OR “prospective study” OR “Randomized controlled trial” OR “RCT”) from January 2006 – May 2021. A total 4 of 19.431 articles recorded at the identification stage by the criteria for inclusion. The articles are randomized controlled trial (RCT). A total of 329 pregnant woman are given various vitamin D supplements with dose range 400 - 4.000 IU. Some article combine with other vitamin (Calcium, Vitamin C+E) with a certain duration. Maternal ages range 20 years - 40 years with an gestational age 6 to more than 32 weeks. Vitamin D can reduce the risk of pre-eclampsia in pregnant women.
Iron Therapies For Iron Deficiency In Chronic Kidney Disease: A Literature Review Zhela Fatin Fatiha; Nining Lestari; Aulia Nissa Rizky Hariyono; Tia Mella Citra; Ayu Mayangsari; Tri Agustina
Journal Research of Social Science, Economics, and Management Vol. 2 No. 3 (2022): Journal Research of Social Science, Economics, and Management
Publisher : Publikasi Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (2353.677 KB) | DOI: 10.59141/jrssem.v2i03.276

Abstract

Chronic kidney disease is a condition when kidney function fails gradually due to kidney damage. One of the causes of anemia in CKD is iron deficiency. Conventional oral iron treatment is not effective to treat iron deficiency anemia due to poor absorption and various side effects. Newer oral iron therapies with better tolerability and offer the potential to normalize iron without the need for intravenous iron. To review the currently available status oral iron therapies and summarizes the latest clinical trial evidence for their use. We researched Google Scholar and PubMed using keyword "iron" OR "ferri" OR "Ferro" OR "iron therapy" AND "Iron deficiency" AND "renal insufficiency, chronic" OR "chronic kidney disease" OR "kidney failure, chronic" OR "chronic renal disease" of last ten years. Total 8 articles recorded the identification stage by the criteria for inclusion. The articles are randomized controlled trials. Total 2.674 patients CKD of various types with or without anemia, age range 18-72 years were treated with oral iron therapies (ferric citrate, ferrous sulfate, sucroferric oxyhydroxide, ferric carboxymaltose) with varying doses. The most side effects of the therapies are gastrointestinal intolerance. Oral iron therapies are considered safe but drug development is still needed to minimize side effects.